Cardiff Oncology, Inc. (CRDF)
$
2.08
-0.09 (-4.33%)
Key metrics
Financial statements
Free cash flow per share
-0.6294
Market cap
144.4 Million
Price to sales ratio
264.3978
Debt to equity
0.0202
Current ratio
4.4211
Income quality
0.8202
Average inventory
0
ROE
-0.7795
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Cardiff Oncology, Inc. is a clinical-stage oncology company based in San Diego, California, specializing in the development of novel cancer treatments for patients. The company's lead drug candidate, onvansertib, is an oral selective Polo-like Kinase 1 Inhibitor designed for anti-cancer therapeutics. In addition to onvansertib, Cardiff Oncology is advancing CY140, which inhibits PLK1, PLK2, and PLK3, currently in phase 1/2 studies for solid tumors and leukemias. The company is actively conducting clinical trials for metastatic colorectal cancer and has another promising candidate, TROV-054, which is in Phase 1b/2 studies combined with FOLFIRI and bevacizumab. Furthermore, Cardiff Oncology's TROV-053 is in Phase II clinical trials in conjunction with Zytiga for metastatic castration-resistant prostate cancer. The diluted EPS is -$0.95 accounting for potential share dilution. The company incurred an interest expense of $0.00 reflecting its debt servicing obligations. The operating income ratio is -71.23 indicating the company's operational profitability margin. Moreover, the net total of other income and expenses is $3,220,000.00 reflecting non-core financial activities. Finally, the EBITDA ratio is -70.64 highlighting the company's operational efficiency. The stock of Cardiff Oncology, Inc. is currently affordable at $4.13 making it suitable for budget-conscious investors. With a high average trading volume of 1,895,380.00 the stock indicates strong liquidity, which is essential for active traders. The company, with a market capitalization of $138,373,870.00 is classified as a small-cap player in the biotechnology space. It is a key player in the oncology industry, contributing significantly to the overall market landscape with its innovative approaches. Furthermore, Cardiff Oncology belongs to the Healthcare sector, driving innovation and growth. This combination of affordability, liquidity, and a strong market position makes Cardiff Oncology an intriguing option for investors looking to engage with a firm that is actively working towards impactful cancer treatments.
Is Cardiff Oncology, Inc. (CRDF) a good investment?
Investing in Cardiff Oncology, Inc. (CRDF) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C+, with a Bullish outlook. Always conduct your own research before investing.
What is Cardiff Oncology, Inc. (CRDF)'s stock forecast?
Analysts predict Cardiff Oncology, Inc. stock to fluctuate between $2.08 (low) and $5.64 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Cardiff Oncology, Inc.'s market capitalization?
As of 2025-08-29, Cardiff Oncology, Inc.'s market cap is $138,373,870, based on 66,525,899 outstanding shares.
How does Cardiff Oncology, Inc. compare to competitors like Meta Platforms, Inc. Class A Common Stock?
Compared to Meta Platforms, Inc. Class A Common Stock, Cardiff Oncology, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Cardiff Oncology, Inc. (CRDF) stock?
To buy Cardiff Oncology, Inc. (CRDF) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for CRDF. Place an order (Market, Limit, etc.).
What is the best time to invest in Cardiff Oncology, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
Has Cardiff Oncology, Inc. stock ever split?
Cardiff Oncology, Inc.'s last stock split was 1:6 on 2019-02-20.
How did Cardiff Oncology, Inc. perform in the last earnings report?
Revenue: $683,000 | EPS: -$0.95 | Growth: 2.15%.
Where can I find Cardiff Oncology, Inc.'s investor relations reports?
Visit https://www.cardiffoncology.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Cardiff Oncology, Inc.?
You can explore historical data from here
What is the all-time high and low for Cardiff Oncology, Inc. stock?
All-time high: $8.58 (2021-09-09) | All-time low: $0.94 (2023-11-10).
What are the key trends affecting Cardiff Oncology, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
benzinga.com
As advancements in cancer treatment continue to evolve, the pursuit of more effective therapies for metastatic colorectal cancer remains a critical focus in the pharmaceutical industry. Cardiff Oncology, Inc. CRDF on Tuesday released data from the ongoing CRDF-004 Phase 2 clinical trial evaluating onvansertib in combination with standard-of-care (SoC) in patients with first-line RAS-mutated metastatic colorectal cancer (mCRC).
seekingalpha.com
Onvansertib continues to show dose-dependent activity in KRAS-mutated mCRC, with response rates improving up to 49% in the high-dose arm. Recent data are less dramatic than early interim results, reflecting typical regression to the mean and leaving some questions unanswered until the next update in Q1 2026. CRDF's cash position is stable for now, but a future financing need is likely as the company advances toward a pivotal phase 3 trial.
zacks.com
Cardiff Oncology (CRDF) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to a loss of $0.26 per share a year ago.
seekingalpha.com
Cardiff Oncology's recent trial data readout delay has unnerved the market, but I see this as a potential buying opportunity for speculative investors. Leadership change is not a major risk factor. The new CMO's pedigree suggests confidence in the company's prospects ahead of the catalyst. The delay could suggest an attempt to improve poor data, or an ability to add to already strong data by waiting for more patient second scans.
marketwatch.com
Sidhu joined Cardiff from Treadwell Therapeutics, where he was medical chief and acting chief executive officer. Previously, Sidhu spent nearly 10 years at Amgen.
globenewswire.com
– Veteran executive with over 20 years of oncology leadership and clinical experience with proven track record of success in bringing development candidates through late-stage clinical development –
zacks.com
Cardiff Oncology (CRDF) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
seekingalpha.com
Cardiff Oncology's onvansertib shows promising early results in improving response rates for RAS-mutated colorectal cancer, with a critical data update expected by mid-2025. Financially, CRDF has sufficient funds to operate until early 2027 but will face funding challenges by 2026, potentially impacting stock value. The success of onvansertib in first-line metastatic colorectal cancer is crucial, with high upside potential but significant risk if upcoming data disappoints.
zacks.com
Cardiff Oncology (CRDF) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
zacks.com
Cardiff Oncology (CRDF) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
See all news
